<DOC>
	<DOCNO>NCT01697696</DOCNO>
	<brief_summary>The purpose study provide long term safety data NVA237 . This study ass safety tolerability single dose strength NVA237 .</brief_summary>
	<brief_title>Long Term Safety Study NVA237 v QAB149 COPD Patients</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Glycopyrrolate</mesh_term>
	<criteria>1 . Male female patient COPD accord GOLD 2011 sign inform consent . 2 . Patients airflow limitation 3080 % postbronchodilator FEV1 runin . 3 . Current exsmokers smoke history least 10 pack year 4 . Patients mMRC score least 2 runin . 1 . Patients contraindicate muscarinic antagonist agent beta2 agonist 2 . Patients history malignancy organ system , treat untreated , within last five year 3 . Patients narrowangle glaucoma , BPH bladderneck obstruction moderatesevere renal impairment urinary retention 4 . Patients COPD exacerbation within 6 week prior screen . 5 . Patients require long term oxygen therapy prescribe 12 hr per day . 6 . Patients history asthma . 7 . Patients onset respiratory symptom , include COPD diagnosis , prior 40 year age . 8 . Patients blood eosinophil count great 600 mm/3 runin 9 . Patients concomitant pulmonary disease 10 . Patients history certain cardiovascular comorbid condition 11 . Patients diagnosis alpha1 antitrypsin deficiency 12 . Patients active pulmonary tuberculosis 13 . Patients active phase pulmonary rehabilitation programme 14 . Other protocoldefined inclusion / exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>COPD , NVA237 , QAB149 , glycopyrronium bromide</keyword>
</DOC>